Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560780 · ClinicalTrials.gov registry record · Phase 3
Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
A Phase 3 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT01560780: Completed Phase 3 study, sponsored by VA Office of Research and Development.
NCT01560780 is a Phase 3 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01560780, a Phase 3 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a randomized-controlled clinical trial that will randomize 120 patients undergoing clinically-indicated coronary artery bypass graft surgery to prasugrel at a dose of 10 mg daily or matching placebo for 12 months, starting at the time of hospital dismissal from surgery. The primary goal of the study is to determine whether prasugrel administration will prevent thrombus (clot) formation within a saphenous vein graft at 12 months, as examined by optical coherence tomography.
Interventions
- DRUG Placebo
- DRUG Prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01560780
The ClinicalTrials.gov registry entry for NCT01560780 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01560780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01560780 about?
NCT01560780 is a clinical study titled "Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis". This is a randomized-controlled clinical trial that will randomize 120 patients undergoing clinically-indicated coronary artery bypass graft surgery to prasugrel at a dose of 10 mg daily or matching placebo for 12 months, starting at the time of hospital dismissal from surgery. The primary goal of t...
What is the current status of trial NCT01560780?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2013-02-01. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT01560780?
The interventions under investigation include: Placebo (DRUG), Prasugrel (DRUG).
Who is sponsoring clinical trial NCT01560780?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.